false
Catalog
2023 World Conference on Lung Cancer (Posters)
EP07.02. Impact of Neoadjuvant Immunotherapy on Su ...
EP07.02. Impact of Neoadjuvant Immunotherapy on Surgical Management for Non-small Cell Lung Cancer:A Multi-center Survey of Current Practice from China - PDF(Abstract)
Back to course
Pdf Summary
This study aimed to investigate the impact of neoadjuvant immunotherapy on the surgical management of non-small cell lung cancer (NSCLC) patients in China. A total of 267 thoracic surgeons from 27 provinces in China participated in an electronic survey. The majority of respondents had over 10 years of experience and worked in high-volume centers. The most common setting for neoadjuvant immunotherapy was central NSCLC of stage III. Surgeons considered tumor size, lymph node metastasis, and probability of complete resection (R0) when deciding on neoadjuvant immunotherapy. Most surgeons chose to perform surgery 4-6 weeks after neoadjuvant immunotherapy, with lobectomy being the most common type of surgery. About 45% of surgeons reported observing immune-related adverse events, which were more common among experienced surgeons. The length and bleeding during surgery were perceived differently by different surgeons, with some perceiving longer operation time and more bleeding while others did not see a significant difference. The majority of surgeons did not believe that neoadjuvant immunotherapy increased the risk of major adverse events during or after surgery. Overall, neoadjuvant immunotherapy was found to result in acceptable adverse events, enhance resectability, and not increase the complexity of surgery for the majority of experienced surgeons.
Asset Subtitle
Han Wu
Meta Tag
Speaker
Han Wu
Topic
Early-Stage NSCLC: New Technology & Innovations
Keywords
neoadjuvant immunotherapy
surgical management
non-small cell lung cancer
NSCLC
China
thoracic surgeons
tumor size
lymph node metastasis
complete resection
lobectomy
×
Please select your language
1
English